A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinitis/rhinoconjunctivitis caused by birch pollen followed by an optional open label, one group safety-extension period. SB/0042 study

Trial Profile

A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinitis/rhinoconjunctivitis caused by birch pollen followed by an optional open label, one group safety-extension period. SB/0042 study

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Sponsors HAL Allergy
  • Most Recent Events

    • 21 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 22 Apr 2016 This trial is Completed in Poland, Czech republic, Slovakia (end date: 3 Feb 2016) and Belgium, according to European Clinical Trials Database
    • 20 Apr 2016 This trial is Completed in Czech republic, Slovakia (end date: 3 Feb 2016) and Belgium, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top